

From: Liverpool-ECMC
Sent: 04 February 2020 15:10
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter February 2020 - Solid Tumours

Follow Up Flag: Follow up
Flag Status: Completed

LIVERPOOL ECMC NEWSLETTER FEBRUARY 2020



ASTRAZENECA JUNIOR INVESTIGATOR MEETING 20TH- 21ST MARCH 2020

AstraZeneca are hosting a Junior Investigator meeting on Friday 20th and Saturday 21st March 2020 in the Malmaison, Manchester.

This meeting is aimed at healthcare professionals who have a clear focus on oncology or immunology, and an interest in actively contributing to clinical and translational research in the UK.

The meeting will address a range of clinical research applications including cancer biology, screening, prevention and diagnosis, with the agenda made up of sessions that focus on the design and performance of oncology-related clinical research as well as methods of data and statistical analysis.

Please click [here](#) to download the agenda.

Information on how to register can be found [here](#).

OPEN RESEARCH WEEK EVENTS 10TH-14TH FEBRUARY 2020



How open practices can get you and your research noticed, published and cited - with Wiley Publishing

Elizabeth Gidney Room, Guild of Students' University of Liverpool, 3.00pm - 4:30pm, Wednesday 12th February 2020

An interactive workshop introducing Registered Reports, FAIRsharing and other open research practices lead by Kathryn Sharples (Senior Director for Open Access at Wiley). Introduced by Professor Bill Greenhalf (Liverpool ECMC)

Health and Open Data (responsible research and the ethics of sharing)

Sensor City, 3:30pm - 6:00pm, Thursday 13th February 2020

The event will be opened by Professor Iain Buchan, Programme Director for Digital Strategy and Partnerships Liverpool Heath Partners and will include talks from Dr Ivan Olier-Caparroso from LJMU and Mary Jane Monaghan from UoL. There will be a workshop organised by Open Data Manchester on Open Data and the challenges in implementing good practice.



NEW STUDIES OPEN

1. CHECKMATE 8KX

"Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy"

Patient population

Adults (≥ 18 years old) male and female subjects with histologic or cytologic evidence of advanced (metastatic and/or unresectable) solid tumour of one of the following tumor types:

- Metastatic squamous or non-squamous NSCLC
- Renal cell carcinoma, advanced or metastatic
- Melanoma
- Hepatocellular carcinoma not amenable for management with curative intent by surgery or local therapeutic measures
- Colorectal cancer, metastatic (MSI-H or dMMR)

2. LECMC BIOMARKER DISCOVERY PROGRAMME

The pancreas cohort of the LECMC Biomarker Discovery Programme (sample collection study) is now open at CCC.

All patients with suspected or actual diagnosed Pancreatic Ductal Carcinoma (PDAC), and those individuals who are undergoing or have been treated for PDAC in the past are potentially eligible for this study.

3. NATIONAL LUNG MATRIX TRIAL

The first CCC patient was recruited to the National Lung Matrix Trial in January. This trial is a multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in **non-small cell lung cancer (NSCLC)**.

Please contact the ECMC Team with any referrals or for further information.

**LIVERPOOL ECMC EARLY
PHASE TRIALS CLINIC IS OPEN**

ecmc

The ECMC Early Phase Trials Clinic is now open. This weekly clinic runs every Monday afternoon at the Clatterbridge Cancer Centre.

Patients who are potentially eligible and interested in participating in phase I and non-randomised phase II clinical trials can be referred to this clinic via the following email address: ccf-tr.ecmcreferrals@nhs.net.



OPEN TRIALS

Please contact Jennie Derham for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293
- E-mail: ccf-tr.ecmcreferrals@nhs.net

ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 2 Study of RPI in Combination with Nivolumab in Patients with Microsatellite Instability High or Mismatch Repair Deficient Tumors – *Melanoma, Non-Melanoma Skin Cancer, Urothelial Bladder Carcinoma*.
- **REPLIMUNE RP2** – An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients *with Solid Tumors*

BREAST

- **CT7001_001** – A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies– *Advanced breast cancer*.
- **GO40987** – A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women with *Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer*
- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer

where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer*.

HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.
- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity*.

HPB / UPPER GI

- **QED BGJ398** - A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy- *Cholangiocarcinoma*

LUNG

- **National Lung Matrix Trial** – Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer.

MELANOMA

- **CirculAting Tumour DNA gUided therapy Switch (CAcTUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma*.

NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

[Find out more...](#)

EVENTS & JOB OPPORTUNITIES

EVENTS

- [Open Research Week Events \(10TH-14TH FEBRUARY 2020\)](#)
- [AstraZeneca Junior Investigator Meeting \(20TH-21ST MARCH 2020\)](#)
- <https://www.ecmcnetwork.org.uk/events>

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via [e-mail](#).

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk